CT 526
Alternative Names: CT-526Latest Information Update: 06 Nov 2023
At a glance
- Originator Cogentis Therapeutics
- Class Antidementias
- Mechanism of Action Cyclin-dependent kinase 5 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Alzheimer's disease; Frontotemporal dementia
Most Recent Events
- 20 Sep 2023 Preclinical trials in Alzheimer's disease in USA (unspecified route) (Cogentis Therapeutics website, September 2023)
- 20 Sep 2023 Preclinical trials in Frontotemporal dementia in USA (unspecified route) (Cogentis Therapeutics website, September 2023)
- 20 Sep 2023 Pharmacodynamics data from preclinical trial in Alzheimer's disease released by Cogentis Therapeutics (Cogentis Therapeutics pipeline, September 2023)